• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由稳定转染子表达的人血管活性肠肽1受体与两种不同的信号通路偶联。

Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways.

作者信息

Sreedharan S P, Patel D R, Xia M, Ichikawa S, Goetzl E J

机构信息

Department of Medicine, University of California, San Francisco 94143-0711.

出版信息

Biochem Biophys Res Commun. 1994 Aug 30;203(1):141-8. doi: 10.1006/bbrc.1994.2160.

DOI:10.1006/bbrc.1994.2160
PMID:8074647
Abstract

Vasoactive intestinal peptide (VIP) is a potent neuropeptide mediator of central and peripheral nervous system function. A human VIP1 receptor (HVR) cDNA clone was previously obtained from HT29 intestinal epithelial cells and lung tissue. Stably-transfected human embryonic kidney 293 cells and chinese hamster ovary (CHO) cells expressing about 10(6) HVRs per cell that bind [125I]VIP with a Kd of 0.2-0.8 nM, and specifically recognized by anti-HVR antibodies, were established and characterized. VIP induced increases in intracellular cAMP levels ([cAMP]i) dose-dependently with an EC50 of 0.2 nM in 293 and CHO stable transfectants and concurrently evoked dose-dependent increases in intracellular calcium concentrations ([Ca2+]i), as determined by fluorescence-dye spectroscopy. Untransfected 293 and CHO cells showed minimal binding or intracellular effects of VIP; however, native VIP1 receptors of HT29 cells also increased [cAMP]i and [Ca2+]i in dose-dependent responses to VIP. Thus recombinant and native human VIP1 receptors both couple to two distinct signal transduction pathways within a single cell type.

摘要

血管活性肠肽(VIP)是中枢和外周神经系统功能的一种强效神经肽介质。人VIP1受体(HVR)cDNA克隆先前已从HT29肠上皮细胞和肺组织中获得。建立并鉴定了稳定转染的人胚肾293细胞和中国仓鼠卵巢(CHO)细胞,这些细胞每细胞表达约10^6个HVR,其与[125I]VIP结合的解离常数(Kd)为0.2 - 0.8 nM,并能被抗HVR抗体特异性识别。在293和CHO稳定转染细胞中,VIP以剂量依赖性方式诱导细胞内cAMP水平([cAMP]i)升高,其半数有效浓度(EC50)为0.2 nM,同时通过荧光染料光谱法测定,VIP还能引起细胞内钙浓度([Ca2+]i)呈剂量依赖性升高。未转染的293和CHO细胞对VIP的结合或细胞内效应极小;然而,HT29细胞的天然VIP1受体对VIP的剂量依赖性反应也会使[cAMP]i和[Ca2+]i升高。因此,重组和天然的人VIP1受体在单一细胞类型中均与两种不同的信号转导途径偶联。

相似文献

1
Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways.由稳定转染子表达的人血管活性肠肽1受体与两种不同的信号通路偶联。
Biochem Biophys Res Commun. 1994 Aug 30;203(1):141-8. doi: 10.1006/bbrc.1994.2160.
2
Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16.
Cell Calcium. 2001 Oct;30(4):229-34. doi: 10.1054/ceca.2001.0230.
3
Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.对II型血管活性肠肽受体具有高效力和选择性的新型环肽激动剂。
J Pharmacol Exp Ther. 1997 May;281(2):629-33.
4
Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties.
Eur J Pharmacol. 1996 Apr 29;302(1-3):207-14. doi: 10.1016/0014-2999(96)00096-9.
5
VIP and PACAP receptor pharmacology: a comparison of intracellular signaling pathways.血管活性肠肽和垂体腺苷酸环化酶激活肽受体药理学:细胞内信号通路比较
Ann N Y Acad Sci. 2006 Jul;1070:239-42. doi: 10.1196/annals.1317.021.
6
Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production.人VIP1受体第一个细胞外环中的天冬氨酸196对于VIP结合及VIP刺激的cAMP产生至关重要。
Biochem Biophys Res Commun. 1997 Jan 13;230(2):289-92. doi: 10.1006/bbrc.1996.5949.
7
Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.垂体腺苷酸环化酶激活多肽I和II受体、血管活性肠肽1以及嵌合氨基末端垂体腺苷酸环化酶激活多肽/血管活性肠肽1受体的特性:多种受体状态的证据
Mol Pharmacol. 1996 Dec;50(6):1596-604.
8
Cloning and expression of the human vasoactive intestinal peptide receptor.
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4986-90. doi: 10.1073/pnas.88.11.4986.
9
Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.垂体腺苷酸环化酶激活多肽/血管活性肠肽受体亚型在垂体克隆生长激素细胞和促性腺激素细胞中的差异表达。
Endocrinology. 1995 May;136(5):2088-98. doi: 10.1210/endo.136.5.7720658.
10
Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor.一种人类神经内分泌血管活性肠肽受体的克隆与功能表达。
Biochem Biophys Res Commun. 1993 Jun 15;193(2):546-53. doi: 10.1006/bbrc.1993.1658.

引用本文的文献

1
Conformational biosensors delineate endosomal G protein regulation by GPCRs.构象生物传感器描绘了GPCR对内体G蛋白的调节作用。
bioRxiv. 2025 May 13:2025.05.12.653522. doi: 10.1101/2025.05.12.653522.
2
Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.靶向 VIP 和 PACAP 受体信号:设计 PACAP 受体亚家族药物的新见解。
Int J Mol Sci. 2022 Jul 22;23(15):8069. doi: 10.3390/ijms23158069.
3
Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.
三叉血管系统中的垂体腺苷酸环化酶激活多肽受体:与偏头痛的关系。
Br J Pharmacol. 2018 Nov;175(21):4109-4120. doi: 10.1111/bph.14053. Epub 2017 Oct 25.
4
Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies.涉及 VPAC 受体激活和调节的机制:来自药理学和突变研究的经验。
Front Endocrinol (Lausanne). 2012 Oct 30;3:129. doi: 10.3389/fendo.2012.00129. eCollection 2012.
5
Pituitary adenylate cyclase-activating polypeptide induces postsynaptically expressed potentiation in the intra-amygdala circuit.垂体腺苷酸环化酶激活肽在杏仁内回路中诱导突触后表达的增强。
J Neurosci. 2012 Oct 10;32(41):14165-77. doi: 10.1523/JNEUROSCI.1402-12.2012.
6
Neurotransmitter influence on human meibomian gland epithelial cells.神经递质对人睑板腺上皮细胞的影响。
Invest Ophthalmol Vis Sci. 2011 Nov 1;52(12):8543-8. doi: 10.1167/iovs.11-8113.
7
VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome.WDHA综合征患者中同时表达血管活性肠肽(VIP)和血管活性肠肽1型受体(VPAC1)的血管活性肠肽瘤
Endocrine. 2009 Apr;35(2):143-6. doi: 10.1007/s12020-009-9146-6. Epub 2009 Jan 30.
8
Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide.缺乏血管活性肠肽诱导型VPAC(2)受体的小鼠迟发型超敏反应增强,速发型超敏反应减弱。
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13854-9. doi: 10.1073/pnas.241503798. Epub 2001 Nov 6.
9
Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.人T淋巴细胞瘤细胞中II型血管活性肠肽受体的主要表达:Ca2+和环磷酸腺苷信号的转导
J Clin Immunol. 1996 Jan;16(1):21-30. doi: 10.1007/BF01540969.
10
The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y1 receptor.对稳定转染神经肽Y Y1受体的人腺癌细胞系进行功能研究。
Br J Pharmacol. 1996 Sep;119(2):321-9. doi: 10.1111/j.1476-5381.1996.tb15989.x.